rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by... It is developed by Insmed and is currently under phase I of the clinical trial.
- Mechanism
- Curator reviewed
rhIGFBP-3 is a protein that is normally found in our bloodstream that has been shown to induce cancer cell death in a variety of experimental systems. Several studies have demonstrated that cancer risk increases with decreasing levels of circulating IGFBP-3. IGFBP-3 can induce cell cycle arrest and enhance the efficacy of chemotherapeutic agents.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with rhIGFBP-3, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account